Klea Pharmaceuticals Joins Forces with Al Khayyat Investments

KLEA HOLDING has launched Klea Pharmaceuticals, a new subsidiary aimed at marketing a portfolio of licensed medicines in the Middle East and Africa. The company expects its first revenues by the second half of 2026. The business will be executed in partnership with Al Khayyat Investments (AKI), a significant player in the healthcare sector in the UAE.

Klea Pharmaceuticals, based in Dubai, has a portfolio of 57 medicines registered under the Emirates Drug Establishment and expects to be fully operational by June 2026. The venture seeks to leverage the robust market demand for healthcare products in the region.

AKI, a leading Emirati holding company, will serve as the pharmaceutical distribution partner, enhancing Klea's market coverage with its extensive logistics and regulatory expertise. AKI's influence in the regional pharmaceutical distribution market is notable, with a 4% market share regionally and 15% in the UAE.